Zacks Investment Research downgraded shares of NEPTUNE TEC&BIO (NEPT) from OUTPERFORM to NEUTRAL on September 04, 2012, with a target price of $5.30.
Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process. Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the nutraceutical and pharmaceutical health and wellness market. The Company develops and markets new formulas and new products for specific applications in high growth markets such the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets, the next wave in nutritional research.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NEPTUNE TEC&BIO (NEPT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment